Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04470778 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT04470778 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 35 participants.
The verdict
NCT04470778, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of gastric pH changes due to famotidine administration on the drug levels of prototype BMS-986256 tablet formulation in healthy participants.
Interventions
- DRUG Famotidine
- DRUG BMS-986256
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2021-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04470778
The ClinicalTrials.gov registry entry for NCT04470778 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Famotidine is the first listed.
NCT04470778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04470778 about?
NCT04470778 is a clinical study titled "Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants". The purpose of this study is to investigate the effect of gastric pH changes due to famotidine administration on the drug levels of prototype BMS-986256 tablet formulation in healthy participants.
What is the current status of trial NCT04470778?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2020-07-20. Estimated completion is 2021-03-28.
What interventions are being tested in trial NCT04470778?
The interventions under investigation include: Famotidine (DRUG), BMS-986256 (DRUG).
Who is sponsoring clinical trial NCT04470778?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.